CCIA
HRMY icon

Campbell & Co Investment Adviser’s Harmony Biosciences HRMY Stock Holding History

Campbell & Co Investment Adviser’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$222K Sell
7,938
-14,158
-64% -$464K 0.01% 949
2025
Q4 		$827K Sell
22,096
-6,775
-23% -$223K 0.04% 635
2025
Q3 		$796K Sell
28,871
-16,036
-36% -$552K 0.06% 516
2025
Q2 		$1.42M Buy
44,907
+31,210
+228% +$1M 0.09% 362
2025
Q1 		$455K Sell
13,697
-6,654
-33% -$239K 0.03% 722
2024
Q4 		$700K Sell
20,351
-18,745
-48% -$644K 0.05% 533
2024
Q3 		$1.56M Buy
39,096
+23,049
+144% +$810K 0.12% 263
2024
Q2 		$484K Sell
16,047
-10,019
-38% -$301K 0.04% 667
2024
Q1 		$875K Buy
26,066
+10,510
+68% +$337K 0.08% 457
2023
Q4 		$502K Buy
15,556
+2,953
+23% +$82.4K 0.05% 712
2023
Q3 		$413K Buy
+12,603
New +$438K 0.05% 601

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Campbell & Co Investment Adviser's HRMY Position: Q1 2026 in Review

Campbell & Co Investment Adviser reduced its Harmony Biosciences (HRMY) stake by 64% in Q1 2026, selling an estimated $464K and leaving 7,938 shares worth $222K. The position accounts for 0.01% of the portfolio, ranked #949.

Campbell & Co Investment Adviser first reported a position in HRMY in Q3 2023 and has held it in 11 quarters since. The position peaked at $1.56M in Q3 2024. 309 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • Campbell & Co Investment Adviser held 7,938 shares of Harmony Biosciences worth $222K as of Q1 2026.
  • Campbell & Co Investment Adviser sold 14,158 Harmony Biosciences shares in Q1 2026, an estimated $464K.
  • Harmony Biosciences made up 0.01% of Campbell & Co Investment Adviser's portfolio in Q1 2026, its #949 holding.
  • Campbell & Co Investment Adviser first reported a position in Harmony Biosciences in Q3 2023 and has held it in 11 quarters since.
  • Campbell & Co Investment Adviser's Harmony Biosciences position peaked at $1.56M in Q3 2024.
  • 309 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.